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(GI) tract and first pass effect can be avoided.[1] Moreover, 
better patient compliance is expected, because this 
system does not require being swallowed as in the case of 
conventional tablet, and therefore beneficial in patients 
with dysphagia or difficulty in swallowing. The use of 
mucoadhesive polymers in the films will enable them to 
adhere to the sublingual mucosa for better retention and 
drug absorption.[2] Ondansetron, a 5HT3 antagonist is a 
potent antiemetic drug, which is used in control of nausea, 
vomiting associated with cancer chemotherapy. It exhibits 
only 60–70% of oral bioavailability because of first pass 
INTRODUCTION
Fast mouth dissolving films have become popular as a new 
delivery system because they are easy to administer and 
sudden-onset  of drug action is possible as the films are 
taken through the sublingual route. Since the sublingual 
mucosa is relatively permeable because of thin membrane 
and is highly perfused, rapid drug absorption and instant 
bioavailability is possible and this leads to quick-onset of 
drug action. Since the drug is directly absorbed into the 
systemic circulation, degradation in the gastrointestinal 
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ABSTRACT
Ondansetron hydrochloride, a 5 HT3 antagonist is a powerful antiemetic drug which has oral bioavailability of 
60% due to hepatic first pass metabolism and has a short half-life of 5 h. To overcome the above draw back, the 
present study was carried out to formulate and evaluate fast dissolving films of ondansetron hydrochloride for 
sublingual administration. The films were prepared from polymers such as polyvinylalcohol, polyvinyl pyrrolidone, 
Carbopol 934P in different ratios by solvent casting method. Propylene glycol or PEG 400 as plasticizers and 
mannitol or sodium saccharin as sweeteners were also included. The IR spectral studies showed no interaction 
between drug and polymer or with other additives. Satisfactory results were obtained when subjected to physico-
chemical tests such as uniformity of weight, thickness, surface pH, folding endurance, uniformity of drug content, 
swelling index, bioadhesive strength, and tensile strength. Films were also subjected to in vitro drug release 
studies by using USP dissolution apparatus. Ex vivo drug permeation studies were carried out using porcine 
membrane model. In vitro release studies indicated 81–96% release within 7 min and 66–80% within 7 min 
during ex vivo studies. Drug permeation of 66–77% was observed through porcine mucosa within 40 min. Higher 
percentage of drug release was observed from films containing the sweeteners. The stability studies conducted 
for a period of 8 weeks showed no appreciable change in drug content, surface pH, and in vitro drug release.
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metabolism and has a relative short half-life of 3–5 h.[3] 
Studies have shown that ondansetron hydrochloride is 
well absorbed through the buccal or sublingual mucosa. [4]
In view of all the above reasons, this study will be an 
attempt to optimize the therapeutic effect of ondansetron 
by formulating as fast mouth dissolving films for sublingual 
use.
MATERIALS AND METHODS
Materials
Ondansetron hydrochloride was obtained as a gift sample 
from Sun Pharma Pvt, Ltd., Ahemadabad. Carbopol 934P 
and Polyvinyl alcohol was obtained from CDH Laboratory. 
Polyvinyl pyrolidone K-30 was procured from Ozone 
International, Mumbai. Mannitol and saccharin sodium were 
laboratory grade ingredients from Loba Chemie, Mumbai.
Preparation  of   fast  dissolving  ondansetron 
hydrochloride film
Fast dissolving films were prepared by solvent casting 
method[5] (Weinberger, 1987). Aqueous solution I was 
prepared by dissolving polymer in 20 mL hot water (80°C) 
with stirring to produce a clear solution and kept for 1 
h to remove all the air bubbles.[6] In the case of the FC 
formulations, Carbopol 934P was first dissolved in a small 
portion of distilled water, neutralized with triethanolamine 
and then added to the cooled Poly Vinyl Alcohol (PVA) 
solution. Aqueous solution II was prepared by dissolving 
pure drug, sweetener, and plasticizer in specific proportion 
in distilled water. The aqueous solutions I and II were mixed 
and stirred for 1 h. The solutions were cast on to 9-cm 
diameter Petri dish and were dried in the oven at 45°C for 
24 h. The films was carefully removed from the Petridish 
and checked for any imperfection and cut according to 
size required for testing (square film 2 cm length, 2 cm 
width) so that each film contained 4 mg of the drug. The 
samples were stored in a glass container maintained at 
temperature 30 °C and relative humidity 60% ± 5% until 
further analysis [Table 1].[2]
Determination of physicochemical parameters
The average weight each of 10 samples of each formulation 
was determined. The thickness of each of sample was 
measured using micrometer screw gauge at five locations, 
and the mean thicknesses were calculated.[6] The folding 
endurance was determined by repeatedly folding one 
film at the same place till it broke or folded up to 300 
times which is considered satisfactory to reveal good film 
properties. The number of times the film could be folded 
at the same place without breaking gives the value of the 
folding endurance. The surface pH of films was determined 
to investigate the possible side effect because of change in 
pH in vivo, since an acidic or alkaline pH may cause irritation 
to buccal mucosa. The film to be tested was placed in a 
Petri dish and was moistened with 0.5 mL of distilled water 
and kept for 30 s. The pH was noted after bringing the 
electrode of the pH meter in contact with the surface of 
the formulation and allowing equilibrating for 1 min. The 
average of 10 determinations for each of the formulation 
was taken.[7] The results for all the films are shown in 
Table 2. The film formulations were also subjected to IR 
spectral studies to determine compatibility between drug 
and other components in the films.
Measurement of swelling index
The studies for swelling index of the film were conducted 
in simulated salivary fluid of pH 6.75. The film sample 
(surface area 4 cm2) was weighed and placed in a preweighed 
stainless steel wire sieve of approximately 800-µm mesh. 
The mesh containing the film sample was submerged into 
50 mL of simulated salivary medium contained in a mortar. 
At definite time interval (30 s), the stainless steel mesh was 
removed, excess moisture removed by carefully wiping 
with absorbent tissue and reweighed. Increase in weight 
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Table 1: Composition of ondansetron fast dissolving films
Ingredient (% w/w) Formulation
FA FB FC
FA1 FA2 FA3 FB1 FB2 FB3 FC1 FC2 FC3
Ondansetron HCl 0.09 0.07 0.09 0.09 0.07 0.09 0.12 0.09 0.12
PVA 52.62 43.95 52.55 59.20 49.44 59.12 80.91 63.72 80.76
PVP 13.15 10.99 13.14 6.58 5.49 6.57 – – –
Carbopol – – – – – – 8.99 7.08 8.97
Propylene glycol 34.14 28.51 34.09 34.14 28.51 34.09 – – --
PEG-400 – – – – – – 9.98 7.86 9.96
Mannitol – 16.48 – – 16.48 – – 21.24 --
Sodium saccharin – – 0.13 – – 0.13 – – 0.18218   J Young Pharm Vol 2 / No 3
of the film was determined at each time interval until a 
constant weight was observed.[8] The degree of swelling 
was calculated using the formula
  Wt - Wo SI =  ,
   Wo
where SI is the swelling index, Wt is the weight of the film 
at time ‘t’, and Wo is the weight of film at t = 0.
Tensile strength measurement
This mechanical property was evaluated using Instron 
Universal Testing Instrument (model F. 4026), Instron Ltd., 
Japan, NITK, Surathkal) with a 5-kg load cell. Film strips 
in special dimension and free from air bubbles or physical 
imperfections were held between two clamps positioned 
at a distance of 3 cm. During measurement, the strips 
were pulled by the top clamp at a rate of 100 mm/min; 
the force and elongation were measured when the film 
broke. Results from film samples, which broke at and not 
between the clamps, were not included in the calculations. 
Measurements were run in triplicate for each film.
Two mechanical properties namely, tensile strength 
(TS) and percentage elongation were computed for the 
evaluation of the film. TS is the maximum stress applied 
to a point at which the film specimen breaks and can be 
computed from the applied load at rupture as a mean of 
three measurements and cross-sectional area of fractured 
film from the following equation.[6]
  Force at break
Tensile strength =   
  Initial cross-sectional area of 
   the sample (mm2)
Percentage elongation can be obtained by following 
equation:
  Increase in length
%Elongation at break =   × 100
  Original length
Uniformity of drug content
This parameter was determined by dissolving one film of 
dimension 2 cm × 2 cm containing 4 mg of ondansetron 
hydrochloride by homogenization in 100 mL of stimulated 
saliva of pH 6.8 for 30 min with continuous shaking. From 
this, 10 mL was diluted to 50 mL with simulated salivary 
fluid. The absorbance was measured at 248 nm using an UV 
spectrometer. The experiments were carried out in triplicate 
for the films of all formulations and average values were 
recorded and given in Table 2.
In vitro dissolution studies
Dissolution profile of fast dissolving films of ondansetron 
hydrochloride was carried out using USP type II (paddle 
apparatus) with 300 mL of simulated salivary fluid (pH 
6.8) as dissolution medium maintained at 37 ± 0.5 °C. 
Medium was stirred at 100 rpm. Samples were withdrawn 
at every 30 s interval, replacing the same amount with 
the fresh medium.[2] Absorbance was determined by UV 
spectrophotometer at 248 nm.
Ex vivo permeation studies through porcine oral 
mucosa
Permeation studies were carried using the modified Franz 
diffusion cell of internal diameter of 2.5 cm. Porcine oral 
mucosa was used as the model membrane. The buccal 
pouch of the freshly killed pig was procured from the 
local slaughter house. The buccal mucosa was excised and 
trimmed evenly from the sides and then washed in isotonic 
phosphate buffer of pH 6.6 and used immediately. The 
membrane was stabilized before mounting to remove the 
soluble components. The mucosa was mounted between 
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Table 2: Physical characterization of film formulations
Formulation code Weight*  
(mg)
Thickness*  
(mm)
Surface  
pH*
% Drug content* Folding endurance* Mucoadhesion time 
(sec)*
FA FA1 51 ± 1.00 0.38 ± 0.015 6.63 ± 0.021 96.59 ± 2.32 >300 150
FA2 60 ± 1.527 0.55 ± 0.081 6.54 ± 0.007 92.60 ± 4.23 >300 90
FA3 55 ± 1.527 0.44 ± 0.052 6.45 ± 0.028 95.80 ± 3.27 >300 120
FB FB1 65 ± 2.516 0.45 ± 0.06 6.49 ± 0.007 91.20 ± 4.13 >300 153
FB2 75 ± 1.527 0.58 ± 0.008 6.20 ± 0.014 86.63 ± 7.04 >300 128
FB3 67 ± 1.00 0.44 ± 0.009 6.32 ± 0.007 90.36 ± 8.95 >300 145
FC FC1 80 ± 1.527 0.58 ± 0.010 7.08 ± 0.001 86.41 ± 5.34 >300 270
FC2 95 ± 2.516 0.71 ± 0.015 6.81 ± 0.021 85.96 ± 5.77 >300 235
FC3 83 ± 1.527 0.64 ± 0.032 7.04 ± 0.021 88.66 ± 2.56 >300 240
*Values represent the mean ± S.D and n=10 for weight and thickness and n=3 for othersJ Young Pharm Vol 2 / No 3  219
the donor and receptor compartments. The receptor 
compartment was filled with 200 mL of isotonic phosphate 
buffer of pH 7.4 which was maintained at 37 °C ± 0.2 °C 
and the hydrodynamics were maintained by stirring with 
a magnetic bead at 50 rpm. One film of dimensions 2 cm 
× 2 cm and previously weighed was placed in intimate 
contact with the mucosal surface of the membrane that 
was previously moistened with a few drops of simulated 
saliva. The donor compartment was filled with 1 mL of 
simulated saliva of pH 6.8. Samples were withdrawn at 
suitable interval, replacing the same amount with the 
fresh medium.[9, 10] The percentage of drug permeated was 
determined by measuring the absorbance in a UV–Visible 
spectrophotometer at 248 nm.
Ex vivo mucoadhesion time and drug release
The ex vivo mucoadhesive time was performed by 
application of the film on freshly cut porcine buccal 
mucosa. The porcine tissues were fixed on the internal 
side of a beaker with cyano acrylate glue. The film was 
wetted with 50 µL of simulated saliva fluid and was pasted 
to the porcine buccal tissue by applying a light force with 
a fingertip for 20 s. The beaker was filled with 200 mL 
simulated saliva fluid and kept at 37 °C. After 2 min, a 50-
rpm stirring rate was applied to simulate the buccal cavity 
environment and during the test, the time taken for the 
film to completely erode or detach from the mucosa was 
observed as the ex vivo mucoadhesion time. A 5-mL sample 
was withdrawn at every 30-s time interval, replacing the 
same amount with fresh medium.[11] After filtration, the 
amount of drug in the withdrawn samples was determined 
by UV spectrophotometer at 248 nm. 
Stability studies
The film formulations were also subjected to stability 
studies by storing them for 8 weeks under environmental 
conditions such as room temperature of 27 ± 2 °C/65% 
RH, oven temperature of 40 ± 2 °C/75% RH and in the 
refrigerator at 4–8 °C. At the end of the period, drug 
content, swelling index, surface pH, and release profiles 
were determined.
RESULTS AND DISCUSSION
Ondansetron film formulations were designed with the 
objective of immediate release of the drug for improved 
patient compliance and better bioavailability. Therefore, 
rapidly water-soluble polymers such as PVA and PVP were 
chosen for the formulation with Carbopol for conferring 
mucoadhesive properties.
All the fabricated film formulations prepared were smooth, 
almost transparent with good flexibility. It was observed 
that result of uniformity of weight; thickness and drug 
content were satisfactory with respect to variation of 
these parameters between films of same formulation. The 
surface pH was close to neutral in all the formulations, 
and this means that they may have less potential to irritate 
the buccal mucosa, therefore more comfortable. All film 
formulations exhibited good folding endurance exceeding 
300, indicating that they are tough and flexible.
The result of IR studies showed no interaction between 
drug, polymer, or excipients with in the formulations. The 
swelling index evaluation indicated that the formulations 
containing mannitol, i.e., FA2, FB2, FC2 exhibited less 
extent of swelling as compared to other formulations. The 
reason may be due to the presence of mannitol, which is 
hydrophilic, since water-soluble salt and sugar increase the 
erosion of the polymer. From this, it is understood that 
the mannitol will cause the disintegration of formulation 
faster compared to formulation without sweetners and 
formulation containing sodium saccharin, which is also 
water-soluble salt but used in lesser concentrations as 
compared to mannitol. Maximum swelling was observed 
for the formulation containing Carbopol as compared 
to those formulations containing PVP as mucoadhesive 
polymer. The swelling index profile for different films is 
shown in Figure 1.
The TS gives an indication of the strength and elasticity of 
the film reflected by the parameters, tensile strength (TS) 
and elongation at break (E/B). A weak and soft polymer 
is characterized by a low TS and E/B; a hard and brittle 
polymer shows a moderate TS and low E/B; a soft and 
tough polymer is characterized by a moderate TS and high 
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Figure 1: Swelling index of different formulation of fast dissolving films 
of ondansetron hydrochloride. (+ – +) FA1, (x–x) FA2, (–) FA3, (º–º) FB1, 
(*–*) FB2, (♦♦)FB3, (■■)FC1, (□□) FC2 
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E/B whereas a hard and tough polymer shows a high TS 
and E/B. The results of TS and percentage elongation of all 
the formulation containing sweetners are shown in Table 3.
The formulation containing mannitol exhibited lower TS 
and % elongation compared to the others. This indicates 
that the presence of water-soluble compound such as 
mannitol and sugars in higher concentration tend to make 
the polymer softer and less tough and therefore poorer 
tensile strength and percentage elongation.
From in vitro drug release studies, it was found that from all 
three set of formulation (FA, FB, and FC), it was found that 
formulation containing mannitol showed high-percentage 
release compared to others. The formulation FA2 showed 
a maximum percentage drug release of 95.69% in 360 s 
followed by the formulation FB2 and FC2 of 92.59% in 
330 s and 85.67% in 420 s, respectively. The order of drug 
release in each set of formulation can be given as:
FA2 > FA3 > FA1
FB2 > FB3 > FB1
FC2 > FC3 > FC1
The in vitro percentage drug release of all formulation is 
given in Table 4. The percentage amount of drug released 
is plotted against time to obtain the release profiles as 
shown in Figure 2. 
From ex vivo drug release studies, it was found that 
formulation-containing mannitol showed highest 
percentage release compared to other formulations. 
The formulation FA2 showed a drug release of 79.69% 
in 330 s. Among the other formulations, it was found 
that formulation FB2 and FC2 showed better percentage 
drug release. The order of drug release in each set of 
formulation can be given as:
FA2 > FA3 > FA1
FB2 > FB3 > FB1
FC2 > FC3 > FC1
The percentage amount of drug released is plotted against 
time to obtain the release profiles as shown in the Figure 3. 
During the ex vivo drug release study, the residence time for 
the formulation, i.e., the time taken for the patch to detach 
or erode completely from the mucosa was observed, and 
it was found that the FC films took longer time, probably 
due to their carbopol content.
Permeation studies through oral mucosa indicated that 
the extent of permeation of ondansetron hydrochloride 
from formulations containing mannitol was observed to 
be much higher than other formulation. The formulation 
FA2 showed the highest percentage of drug permeated, 
Table 3: Results of tensile strength and percentage 
elongation for all films
Formulation code Tensile strength*, kg/mm2 % Elongation*
FA1 1.141 ± 0.3 103.33 ± 3.02
FA2 0.846 ± 0.2 93.33 ± 2.14
FA3 1.023 ± 0.7 100.23 ± 3.19
FB1 1.444 ± 0.1 165.66 ± 2.22
FB2 1.151 ± 0.3 156.56 ± 2.76
FB3 1.334 ± 0.5 160.66 ± 1.36
FC1 0.817 ± 0.4 136.67 ± 4.63
FC2 0.788 ± 0.1 126.56 ± 3.16
FC3 0.802 ± 0.5 132.15 ± 1.54
*Values are represented as mean ± SD and n = 3
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Table 4: Results of in vitro drug release from films into simulated saliva using U.S.P Dissolution Test Apparatus I
Time (s)
(Sec)
Percentage drug dissolved in simulated saliva*
FA FB FC
FA1 FA2 FA3 FB1 FB2 FB3 FC1 FC2 FC3
30 15.45 ± 1.02 20.61 ±1.44 16.18 ± 0.10 11.99 ± 0.36  14.61 ± 0.48 15.56 ± 0.26 12.66 ± 1.19 17.23 ± 1.76  16.83 ± 0.44
60 23.31 ± 1.11 32.45 ± 0.61 24.79 ± 0.24 18.39 ± 0.29 21.65 ± 0.72 22.42 ±1.38 19.41 ± 0.49 25.55 ± 0.08 22.26 ± 0.32
90 34.25 ± 0.75 39.63 ± 0.36 37.12 ± 0.09 27.07 ± 1.84 33.63 ± 0.27 26.67 ± 1.07 26.84 ± 0.45 32.08 ± 1.05 33.43 ±1.11
120 42.30 ± 1.32 51.67 ± 0.24 47.42 ± 1.07 33.42 ± 0.72  44.09 ± 1.74 33.67 ± 1.28 35.27 ± 1.07 42.60 ± 2.11 40.35 ± 1.35
150 55.91 ± 0.46 61.57 ± 0.13 58.34 ± 0.77 41.71 ± 0.33 54.95 ± 1.49 40.01 ± 1.48 45.45 ± 0.75 56.15 ± 1.73 51.54 ± 0.47
180 62.22 ± 0.37 71.74 ± 0.05 63.64 ± 1.11 53.51 ± 0.22 63.23 ± 2.01 45.76 ± 1.17 55.98 ± 2.56 64.94 ± 0.82 61.85 ± 0.11
210 68.59 ± 1.62 79.83 ± 1.21 70.07 ± 0.18 60.03 ± 1.23 73.20 ± 1.23 53.76 ± 0.20 63.37 ± 1.05 70.13 ± 1.38 66.85 ± 1.09
240 75.26 ± 0.83 89.63 ± 0.17 78.50 ± 0.57 65.06 ± 0.95  85.07 ± 1.06 65.93 ± 0.09 71.62 ± 1.14 77.21 ± 1.54 71.43 ± 0.35
270 81.21 ± 0.44 94.82 ± 0.65 84.92 ± 1.08 68.01 ± 1.34 91.55 ± 0.42 77.35 ± 1.03 76.51 ± 0.87 84.44 ± 1.12 76.58 ± 0.99
300 86.73 ± 0.74 95.44 ± 0.13 89.59 ± 0.09 72.38 ± 0.45 92.40 ± 1.07 84.30 ± 0.49 78.29 ± 0.24 85.51 ± 0.32 78.29 ± 1.23
330 88.75 ± 0.78 95.66 ± 0.57 92.71 ± 1.47 77.80 ± 1.47 92.59 ± 1.11 90.23 ± 0.38 83.23 ± 1.94 85.65 ± 1.03 80.28 ± 0.24
360 88.88 ± 1.06 95.69 ± 1.13 92.82 ± 1.93 80.62 ± 1.86 – 91.33 ± 2.14 85.27 ± 0.31 85.67 ± 0.85 85.01 ± 1.08
390 – – – 81.19 ± 0.54 – 91.38 ± 1.95 85.71 ± 1.08 – 86.61 ± 0.25
420 – – – 81.27 ± 0.93 – – 85.79 ± 0.93 – 86.71 ± 0.67
*Values are represented as mean ± SD and n = 3J Young Pharm Vol 2 / No 3  221
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i.e., 77.01% in 30 min. The percentage drug permeated 
was plotted against the time to obtain the profiles as shown 
in Figure 4.
The results of stability studies of ondansetron hydrochloride 
fast dissolving films showed no significant change with 
respect to drug content, surface pH, swelling index, and 
in vitro drug release at the end of 8 weeks when stored in 
above-mentioned conditions.
CONCLUSION
The use of water-soluble sweeteners, especially mannitol 
not only enhanced the taste of the ondansetron containing 
films, but also increased drug release and drug permeation 
through oral mucosa. On the basis of data obtained from in 
vitro dissolution and ex vivo permeation studies that FA2 and 
FB2 are promising formulations suitable for the immediate 
release of ondansetron for systemic use since they exhibited 
maximum drug release and permeation, respectively.
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Figure 2: In vitro dissolution profile of ondansetron hydrochloride from 
all films. (+ - +) FA1, (x–x) FA2, (--) FA3, (▲▲) FB1, (*-*) FB2, (♦♦) FB3, 
(□□) FC1, (■■) FC2, (▪▪) FC3
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Figure 4: Permeation profile of ondansetron hydrochloride from all 
formulation through porcine buccal mucosa. (+ - +) FA1, (--) FA2, (□□) 
FA3, (x-x) FB1, (*-*) FB2, (■■)FB3, (▪▪) FC1, (◦◦) FC2, (▲▲) FC3.
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